Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2008-09-29

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.00699-08PMID 18824605PMCID PMC2592891
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.

  2011cited by this paper
• 855 ONCE-DAILY REGIMENS OF THE HCV NS3/4A-PROTEASE INHIBITOR TMC435350 ARE PREDICTED TO PROVIDE THERAPEUTIC EXPOSURE IN PLASMA AND LIVER

  2008cited by this paper
• Randomized trial of interferon beta‐1a with or without ribavirin in Asian patients with chronic hepatitis C

  2007cited by this paper
• Results of a Phase I Placebo-Controlled Trial in Healthy Volunteers to Examine the Safety, Tolerability and PK of the HCV Protease Inhibitor TMC435350 after Single and Repeated Dosing

  2007cited by this paper
• Antiviral activity of telaprevir (VX‐950) and peginterferon alfa‐2a in patients with hepatitis C

  2007cited by this paper
• [786] RESULTS OF AN INTERIM ANALYSIS OF A PHASE 2 STUDY OF TELAPREVIR (VX-950) WITH PEGINTERFERON a-2a AND RIBAVIRIN IN PREVIOUSLY UNTREATED SUBJECTS WITH HEPATITIS C

  2007cited by this paper
• SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.

  2007cited by this paper
• Relative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon System

  2007cited by this paper
• Palmitic acid induces production of proinflammatory cytokine interleukin‐8 from hepatocytes

  2007cited by this paper
• Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.

  2007cited by this paper
• Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro.

  2007cited by this paper
• Telaprevir and pegylated interferon–alpha‐2a inhibit wild‐type and resistant genotype 1 hepatitis C virus replication in patients

  2007cited by this paper
• Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease

  2006influential reference
• A target on the move: innate and adaptive immune escape strategies of hepatitis C virus.

  2006cited by this paper
• Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

  2006cited by this paper
• 12 Wild-type HCV NS3 protease re-emerges during follow-up after 14 days of dosing with VX-950 in patients with genotype 1 HCV

  2006cited by this paper
• Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study.

  2006influential reference
• Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor:

  2006cited by this paper
• Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic.

  2006cited by this paper
• Evasion of intracellular host defence by hepatitis C virus

  2005cited by this paper
• “Strong reasons make strong actions” — The antiviral efficacy of NS3/4A protease inhibitors

  2005cited by this paper
• Global epidemiology of hepatitis C virus infection.

  2005cited by this paper
• In Vitro Studies of Cross-resistance Mutations against Two Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061*

  2005cited by this paper
• Global Transcriptional Profiling Demonstrates the Combination of Type I and Type II Interferon Enhances Antiviral and Immune Responses at Clinically Relevant Doses

  2005cited by this paper
• Antiviral efficacy of NS3‐serine protease inhibitor BILN‐2061 in patients with chronic genotype 2 and 3 hepatitis C

  2005cited by this paper
• Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

  2004cited by this paper
• Viral Evolution and Interferon Resistance of Hepatitis C Virus RNA Replication in a Cell Culture Model

  2004influential reference
• Progress and development of small molecule HCV antivirals.

  2004cited by this paper
• Hepatitis C: it's a long way to new therapy, it's a long way to go...

  2004cited by this paper
• Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection

  2003cited by this paper
• An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

  2003influential reference
• 972 VX-950: the discovery of an inhibitor of the hepatitis C NS3·4A protease and a potential hepatitis C virus therapeutic

  2003cited by this paper
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  2002cited by this paper
• NIH Consensus Statement on Management of Hepatitis C: 2002.

  2002cited by this paper
• The myotoxicity of statins

  2002cited by this paper
• Effects of HMG-CoA Reductase Inhibitors on Skeletal Muscle

  2002cited by this paper
• Rational approach to the clinical protocol design for drug combinations: a review.

  2000cited by this paper
• Slow-binding inhibition: the general case.

  1996cited by this paper
• Kinetics of slow and tight-binding inhibitors.

  1995cited by this paper
• A three-dimensional model to analyze drug-drug interactions.

  1990cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984influential reference
• [17] The kinetics of reversible tight-binding inhibition

  1979cited by this paper
• The kinetics of reversible tight-binding inhibition.

  1979cited by this paper
• Transition state analog inhibitors and enzyme catalysis.

  1976cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Endogenous EWSR1-FLI1 degron alleles enable control of fusion oncoprotein expression in tumor cell lines and xenografts

  2024cites this paper
• Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel Strategies

  2024cites this paper
• Structure-based virtual screening of natural compounds against wild and mutant (R1155K, A1156T and D1168A) NS3-4A protease of Hepatitis C virus

  2023cites this paper
• Synthetic approaches and application of clinically approved small-molecule drugs to treat hepatitis.

  2023cites this paper
• Viral proteases as therapeutic targets

  2022cites this paper
• A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval

  2022cites this paper
• COVID-19 and Dentistry in 72 Questions: An Overview of the Literature

  2021cites this paper
• Potential drug development and therapeutic approaches for clinical intervention in COVID-19

  2021cites this paper
• Curing Hepatitis C with Direct‐Acting Antiviral Therapy

  2021cites this paper
• SARS-CoV-2 therapeutics: how far do we stand from a remedy?

  2021cites this paper
• Efficacy and safety of danoprevir plus sofosbuvir in GT 1, 2, 3, or 6 chronic hepatitis C patients with or without cirrhosis in China

  2021influential citation
• First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients

  2020cites this paper
• Impact of IFN-Free and IFN-Based Treatment on Blood Myeloid Dendritic Cell, Monocyte, Slan-DC, and Activated T Lymphocyte Dynamics during HCV Infection

  2020cites this paper
• Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy

  2020influential citation
• First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients

  2020cites this paper
• Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy

  2020cites this paper
• COVID-19 treatment: Much research and testing, but far, few magic bullets against SARS-CoV-2 coronavirus

  2020cites this paper
• Changes of inflammatory cytokines/chemokines during ravidasvir plus ritonavir‐boosted danoprevir and ribavirin therapy for patients with genotype 1b hepatitis C infection

  2020cites this paper
• Tailor-Made Amino Acids and Fluorinated Motifs as Prominent Traits in the Modern Pharmaceuticals.

  2020cites this paper
• Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naïve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China

  2019cites this paper
• Resistance outside the substrate envelope: hepatitis C NS3/4A protease inhibitors

  2019cites this paper
• The Invention of Grazoprevir: An HCV NS3/4a Protease Inhibitor

  2019cites this paper
• Evolution of HCV NS3/4a Protease Inhibitors

  2019cites this paper
• Visualization of Positive and Negative Sense Viral RNA for Probing the Mechanism of Direct-Acting Antivirals against Hepatitis C Virus

  2019cites this paper
• The role of N-terminal heterocycles in hydrogen bonding to α-chymotrypsin.

  2019cites this paper
• Rational design of antiviral drug combinations based on equipotency using HCV subgenomic replicon as an in vitro model.

  2018cites this paper
• Chemogenetic control of gene expression and cell signaling with antiviral drugs

  2018cites this paper
• GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo

  2018cites this paper
• Explorer Development of an Intergenotypic Hepatitis C Virus ( HCV ) Cell Culture Method To Assess Antiviral Susceptibilities and Resistance Development of HCV NS 3 Protease Genes from HCV Genotypes 1 to 6

  2017cites this paper
• Direct-Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection

  2017cites this paper
• Efficient replication of blood‐borne hepatitis C virus in human fetal liver stem cells

  2017cites this paper
• The Second-generation of Highly Potent Hepatitis C Virus (HCV) NS3/4A Protease Inhibitors: Evolutionary Design Based on Tailor-made Amino Acids, Synthesis and Major Features of Bio-activity.

  2017cites this paper
• Overview of Macrocycles in Clinical Development and Clinically Used

  2017cites this paper
• Antioxidant and biological activities of tyrosol, hydroxytyrosol and their esters

  2017cites this paper
• Synthetic Strategy and Anti-Tumor Activities of Macrocyclic Scaffolds Based on 4-Hydroxyproline

  2016cites this paper
• Pyrazolo[1,5-a]pyrimidine-based macrocycles as novel HIV-1 inhibitors: a patent evaluation of WO2015123182

  2016cites this paper
• Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry.

  2016cites this paper
• Understanding Drug Resistance and Antibody Neutralization Escape in Antivirals: A Dissertation

  2016cites this paper
• Effect of D168V mutation in NS3/4A HCV protease on susceptibilities of faldaprevir and danoprevir.

  2016cites this paper
• Triple Therapy with First Generation Protease Inhibitors for Hepatitis C Markedly Impairs Function of Neutrophil Granulocytes

  2016cites this paper
• A software for parameter optimization with Differential Evolution Entirely Parallel method

  2016cites this paper
• New directions for protease inhibitors directed drug discovery

  2016cites this paper
• Molecular principles behind Boceprevir resistance due to mutations in hepatitis C NS3/4A protease.

  2015cites this paper
• Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor.

  2015cites this paper
• Hepatitis C Virus: Structural Insights into Protease Inhibitor Efficacy and Drug Resistance: A Dissertation

  2015cites this paper
• LC-ESI-MS/MS Analysis and Pharmacokinetics of GP205, an Innovative Potent Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease in Rats

  2015cites this paper
• [Successful eradication of genotype 4 HCV with telaprevir-based triple antiviral therapy].

  2014cites this paper
• A Pharmacokinetic/Viral Kinetic Model to Evaluate the Treatment Effectiveness of Danoprevir against Chronic HCV

  2014influential citation
• Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.

  2014cites this paper
• Accounting for strain variations and resistance mutations in the characterization of hepatitis C NS3 protease inhibitors

  2014cites this paper
• Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy.

  2014cites this paper
• HCV-targeted antivirals: current status and future challenges.

  2014cites this paper
• Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.

  2014cites this paper
• Hepatitis C virus molecular evolution: Transmission, disease progression and antiviral therapy

  2014cites this paper
• Two-way interaction study between ritonavir boosted danoprevir, a potent HCV protease inhibitor, and ketoconazole in healthy subjects.

  2014cites this paper
• Structural Analysis of Asunaprevir Resistance in HCV NS3/4A Protease

  2014cites this paper
• Key Binding and Susceptibility of NS3/4A Serine Protease Inhibitors against Hepatitis C Virus

  2014cites this paper
• A New Stochastic Model for Subgenomic Hepatitis C Virus Replication Considers Drug Resistant Mutants

  2014influential citation
• Computational Study on the Drug Resistance Mechanism against HCV NS3/4A Protease Inhibitors Vaniprevir and MK-5172 by the Combination Use of Molecular Dynamics Simulation, Residue Interaction Network, and Substrate Envelope Analysis

  2014cites this paper
• uccessful eradication of enotype 4 HCV with elaprevir-based triple antiviral herapy rradicación exitosa del virus de la hepatitis , genotipo 4 , con terapia triple antiviral stándar más telaprevir

  2014cites this paper
• In silico screening for potent inhibitors against the NS3/4A protease of hepatitis C virus.

  2014cites this paper
• Resistance mutations against HCV protease inhibitors and antiviral drug design.

  2014cites this paper
• Erradicación exitosa del virus de la hepatitis C, genotipo 4, con terapia triple antiviral estándar más telaprevir

  2014cites this paper
• Effect of meal and antisecretory agents on the pharmacokinetics of danoprevir/ritonavir in healthy volunteers

  2014cites this paper
• Identification of the NS5B S282T Resistant Variant and Two Novel Amino Acid Substitutions That Affect Replication Capacity in Hepatitis C Virus-Infected Patients Treated with Mericitabine and Danoprevir

  2014cites this paper
• Effect of Ritonavir‐Boosted Danoprevir, a Potent Hepatitis C Virus Protease Inhibitor, on the Pharmacokinetics of Methadone in Healthy Subjects Undergoing Methadone Maintenance Therapy

  2014cites this paper
• Challenges and Opportunities for Scaling the Ring‐Closing Metathesis Reaction in the Pharmaceutical Industry

  2014cites this paper
• Successful eradication of genotype 4 HCV with telaprevir-based triple antiviral therapy

  2014cites this paper
• Preclinical pharmacokinetics and in vitro metabolism of BMS-605339: a novel HCV NS3 protease inhibitor.

  2014cites this paper
• Dynamic kinetic resolution of dehydrocoronamic acid.

  2014cites this paper
• Successful eradication of genotype 4 HCV with telaprevir-based triple antiviral therapy

  2014cites this paper
• The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection.

  2014cites this paper
• Development of Related HCV Protease Inhibitors: Macrocyclization of Two Highly Functionalized Dienyl-ureas via Ring-Closing Metathesis

  2013cites this paper
• Characterization of HCV Protease Inhibitors : Inhibition and Interaction Studies with Applications for Drug Discovery

  2013cites this paper
• Pharmacokinetics of a Three-Way Drug Interaction Between Danoprevir, Ritonavir and the Organic Anion Transporting Polypeptide (OATP) Inhibitor Ciclosporin

  2013cites this paper
• Observed in Clinical Studies of Telaprevir Hepatitis C Virus NS3 Protease Variants Phenotypic Characterization of In Vitro

  2013cites this paper
• How to optimize HCV therapy in genotype 4 patients

  2013cites this paper
• Replication of the subgenomic hepatitis C virus replicon in the presence of the NS3 protease inhibitors: a stochastic model

  2013cites this paper
• Concise asymmetric synthesis of a (1R,2S)-1-amino- 2-vinylcyclopropanecarboxylic acid-derived sulfonamide and ethyl ester.

  2013cites this paper
• Update on the Development of Anti-Viral Agents Against Hepatitis C

  2013cites this paper
• New horizons in hepatitis C antiviral therapy with direct‐acting antivirals

  2013influential citation
• A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail

  2013cites this paper
• Boron chemicals in diagnosis and therapeutics.

  2013cites this paper
• Discovery of novel P2 substituted 4-biaryl proline inhibitors of hepatitis C virus NS3 serine protease.

  2013cites this paper
• Role of Proteases in the Management of Hepatitis C Virus

  2013cites this paper
• Hepatitis C Virus: From Molecular Virology to Antiviral Therapy

  2013cites this paper
• Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance.

  2013cites this paper
• HCV Infection and NS-3 Serine Protease Inhibitors

  2013cites this paper
• Effect of Ritonavir‐Boosted Danoprevir, a Potent Hepatitis C Virus Protease Inhibitor, on QTc Interval in Healthy Subjects: Results from a Thorough QT Study

  2013cites this paper
• Enhanced Differential Evolution Entirely Parallel Method for Biomedical Applications

  2013cites this paper
• Prise en charge de l’hépatite C chronique : les dernières avancées thérapeutiques

  2013cites this paper
• Hepatitis C virus-specific directly acting antiviral drugs.

  2013cites this paper
• Antiviral Drug Discovery

  2013cites this paper
• In Vitro Phenotypic Characterization of Hepatitis C Virus NS3 Protease Variants Observed in Clinical Studies of Telaprevir

  2013cites this paper
• Efficacy and Safety of Danoprevir-Ritonavir plus Peginterferon Alfa-2a–Ribavirin in Hepatitis C Virus Genotype 1 Prior Null Responders

  2013cites this paper
• Hepatitis C Virus Non-Structural Protein 3/4A: A Tale of Two Domains: A Dissertation

  2012cites this paper
• Understanding the drug resistance mechanism of hepatitis C virus NS3/4A to ITMN-191 due to R155K, A156V, D168A/E mutations: a computational study.

  2012cites this paper
• Characterization of Resistance to the Protease Inhibitor GS-9451 in Hepatitis C Virus-Infected Patients

  2012cites this paper
• The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors

  2012cites this paper
• Canine Hepacivirus NS3 Serine Protease Can Cleave the Human Adaptor Proteins MAVS and TRIF

  2012cites this paper